Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia

Haematologica

Volumn 96, Issue 11, 2011, Pages 1605-1612

  Musallam, Khaled M ^a   Cappellini, Maria Domenica ^b   Wood, John C ^c   Motta, Irene ^b   Graziadei, Giovanna ^b   Tamim, Hani ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Endocrine disease; Iron overload; Liver iron concentration; Osteoporosis; Thalassemia intermedia; Vascular disease

Indexed keywords

FERRITIN; HEMOGLOBIN; HEMOGLOBIN F; IRON;

ADULT; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE DISEASE; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOCRINE DISEASE; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; ITALY; LEBANON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PHENOTYPE; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOSIS; VASCULAR DISEASE;

ADULT; BETA-THALASSEMIA; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOOD TRANSFUSION; CROSS-SECTIONAL STUDIES; ERYTHROCYTE COUNT; ERYTHROCYTES, ABNORMAL; FEMALE; FERRITINS; FETAL HEMOGLOBIN; HUMANS; IRON; IRON OVERLOAD; LIVER; MALE; MIDDLE AGED; PLATELET COUNT; SPLENECTOMY;

EID: 80455143324     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.047852     Document Type: Article

References (48)

1. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Disorders of hemoglobin: genetics pathophysiology, and clinical management. 2nd ed. Cambridge: Cambridge University Press, 2009.
2. Taher AT, Musallam KM, Karimi M, El- Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886-92.
3. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of beta thalassaemia intermedia. Br J Haematol. 2011;152(5):512-23.
4. Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S, et al. Levels of non-transferrin- bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009;146(5):569-72.
5. Taher A, El Rassi F, Isma'eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584-6.
6. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583-8.
7. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol. 2009;147(5):634-40.
8. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47 (5):792-800.
9. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost. 2010;8(1):54-9.
10. O'Donnell A, Premawardhena A, Arambepola M, Allen SJ, Peto TE, Fisher CA, et al. Age-related changes in adaptation to severe anemia in childhood in developing countries. Proc Natl Acad Sci USA. 2007;104(22):9440-4.
11. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Agerelated complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol. 2010;150(4):486-9.
12. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364(2):146-56.
13. Roghi A, Cappellini MD, Wood JC, Musallam KM, Patrizia P, Fasulo MR, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol. 2010;89(6):585-9.
14. Taher AT, Musallam KM, Wood JC, Cappellini MD. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol. 2010;85(4):288-90.
15. Origa R, Barella S, Argiolas GM, Bina P, Agus A, Galanello R. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica. 2008;93(7):1095-6.
16. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327-31.
17. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-61.
18. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2*mapping accurately estimates hepatic iron concentration in transfusiondependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-5.
19. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22 (23):2171-9.
20. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-61.
21. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100(1):17-21.
22. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971-7.
23. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101(1):91-6.
24. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-73.
25. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995;80(1):58-68.
26. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):40S-7S.
27. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme inhibition on progression of chronic heart failure: results of the Munich Mild Heart Failure Trial. Br Heart J. 1992;67(4):289-96.
28. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
29. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8(6):457-69.
30. El-Hajj Fuleihan G, Baddoura R, Awada H, Arabi A, Okais J. First update of the Lebanese guidelines for osteoporosis assessment and treatment. J Clin Densitom. 2008;11(3):383-96.
31. Fung EB, Harmatz PR, Lee PD, Milet M, Bellevue R, Jeng MR, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol. 2006;135 (4):574-82.
32. Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann NY Acad Sci. 2010;1202:231-6.
33. Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96 (4):488-91.
34. Taher AT, Musallam KM, Karimi M, El- Beshlawy A, Belhoul K, Daar S, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010;8(10):2152-8.
35. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111(2):467-73.
36. Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksiri P, et al. Pulmonary arterial hypertension in previously splenectomized patients with betathalassemic disorders. Int J Hematol. 2003;78(2):139-45.
37. Sundaram N, Tailor A, Mendelsohn L, Wansapura J, Wang X, Higashimoto T, et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010;116(1):109-12.
38. Balla J, Vercellotti GM, Nath K, Yachie A, Nagy E, Eaton JW, et al. Haem, haem oxygenase and ferritin in vascular endothelial cell injury. Nephrol Dial Transplant. 2003;18 (Suppl 5):v8-12.
39. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 2010;120(12):4466-77.
40. Ramos P, Melchiori L, Gardenghi S, Van- Roijen N, Grady RW, Ginzburg Y, et al. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models. Ann NY Acad Sci. 2010;1202:24-30.
41. Oliva EN, Ronco F, Marino A, Alati C, Pratico G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50(7):1568-70.
42. Li H, Rybicki AC, Suzuka SM, von Bonsdorff L, Breuer W, Hall CB, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16 (2):177-82.
43. Borenstain-Ben Yashar V, Barenholz Y, Hy- Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993;44(1):63-5.
44. Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia. Hematol Oncol Clin North Am. 2010;24(6):1089-107.
45. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411-6.
46. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127 (5):1523-30.
47. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007;92(5):658-65.
48. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14(3):183-90.